Clinical Trials · NCT01431391
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Dendreon
- Enrollment
- 68
- Start date
- Sep 2011
- Locations
- 14 sites, United States
- Primary endpoint
- Immune Response at Month 24 as Evaluated by IFN-γ ELISPOT Specific for PA2024